The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed nephrology journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Centers for Disease Control and Prevention (CDC) Chronic Kidney Disease Surveillance System, National Institutes of Health (NIH) Kidney Disease Statistics, National Center for Biotechnology Information (NCBI/PubMed), World Health Organization (WHO) Global Burden of Disease Database, US Renal Data System (USRDS), European Renal Association (ERA) Registry, International Society of Nephrology (ISN), National Kidney Foundation (NKF), American Society of Nephrology (ASN), Eurostat Health Database, and national health ministry reports from key markets.
For membranous nephropathy, IgA nephropathy, lupus nephritis, focal segmental glomerulosclerosis, and minimal change disease, these sources were used to gather data on disease prevalence, clinical safety studies, therapy recommendations, and market landscape analysis.
In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, vice presidents of clinical development, heads of regulatory affairs, and commercial directors from pharmaceutical companies and biotech firms creating treatments for glomerulonephritis were examples of supply-side sources. Board-certified nephrologists, renal transplant specialists, clinical pharmacists, and procurement leaders from hospital nephrology departments, dialysis facilities, specialty renal clinics, and academic medical centers were examples of demand-side sources. Primary study obtained information on clinical adoption patterns, treatment procedures, pricing strategies, and reimbursement dynamics in addition to validating market segmentation and product pipeline timelines.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and treatment volume analysis. The methodology included:
Identification of 40+ key pharmaceutical and biotechnology companies across North America, Europe, Asia-Pacific, and Latin America
Product mapping across immunosuppressive therapy, corticosteroids, biologics, and other therapeutic categories
Analysis of reported and modeled annual revenues specific to glomerulonephritis treatment portfolios
Coverage of manufacturers representing 65-70% of global market share in 2024
Extrapolation using bottom-up (treatment volume × ASP by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations